LifeStance Health Group (NASDAQ:LFST) Trading Up 9.4% on Earnings Beat

Key Points

• LifeStance Health Group (NASDAQ:LFST) shares increased by 9.4% after reporting an earnings per share (EPS) of ($0.01), surpassing estimates of ($0.03).
• The company announced quarterly revenue of $345.31 million, slightly exceeding analyst expectations and representing a 10.6% year-over-year increase.
• Analysts have upgraded the stock, with a consensus price target of $8.42, indicating a potential upside given the recent price of around $4.22.

LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report)'s share price rose 9.4% on Friday following a stronger than expected earnings report. The stock traded as high as $4.21 and last traded at $4.22. Approximately 1,027,917 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 1,867,974 shares. The stock had previously closed at $3.86.

The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. LifeStance Health Group had a negative return on equity of 2.47% and a negative net margin of 2.78%. The business had revenue of $345.31 million for the quarter, compared to analyst estimates of $345.05 million. During the same quarter in the prior year, the firm posted ($0.06) EPS. The firm's revenue for the quarter was up 10.6% on a year-over-year basis.

Analyst Upgrades and Downgrades

LFST has been the subject of several analyst reports. UBS Group raised shares of LifeStance Health Group from a "neutral" rating to a "buy" rating and set a $8.50 price target for the company in a report on Tuesday, May 27th. BTIG Research began coverage on LifeStance Health Group in a report on Friday, July 25th. They issued a "buy" rating and a $8.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $8.42.

Insiders Place Their Bets

In other LifeStance Health Group news, insider Ujjwal Ramtekkar sold 16,000 shares of the business's stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $5.94, for a total transaction of $95,040.00. Following the sale, the insider directly owned 113,435 shares of the company's stock, valued at $673,803.90. The trade was a 12.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 3.20% of the company's stock.

Institutional Trading of LifeStance Health Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in shares of LifeStance Health Group by 5.0% in the 1st quarter. Vanguard Group Inc. now owns 11,221,237 shares of the company's stock valued at $74,733,000 after purchasing an additional 531,841 shares during the period. Jennison Associates LLC increased its position in LifeStance Health Group by 2.1% during the first quarter. Jennison Associates LLC now owns 8,255,236 shares of the company's stock worth $54,980,000 after buying an additional 168,856 shares during the last quarter. Wellington Management Group LLP raised its stake in LifeStance Health Group by 2.3% in the first quarter. Wellington Management Group LLP now owns 5,399,293 shares of the company's stock valued at $35,959,000 after buying an additional 123,056 shares during the period. Dimensional Fund Advisors LP raised its stake in LifeStance Health Group by 87.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,524,529 shares of the company's stock valued at $25,977,000 after buying an additional 1,643,390 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of LifeStance Health Group by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 3,465,471 shares of the company's stock valued at $25,546,000 after buying an additional 13,293 shares during the last quarter. Institutional investors own 85.50% of the company's stock.

LifeStance Health Group Price Performance

The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $1.59 billion, a P/E ratio of -40.73 and a beta of 1.13. The company has a 50 day moving average price of $4.80 and a 200 day moving average price of $6.22.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.